Arlinda Lee

New York , New York, United States
Arlinda Lee is currently a biotechnology analyst at Canaccord Genuity. Prior to, she was a healthcare analyst at MLV & Co., a biotechnology analyst ay CRT Capital Group, Vice President of Biotechnology at Barclays Capital, Vice President and Senior Biotechnology Analyst at First Tennessee National, Vice President at Bear Sterns and biotechnology analyst at Punk, Ziegel & Company. Arlinda earned a Ph.D., in genetics from Stony Brook University and a B.A. in molecular genetics and rhetoric from the University of California, Berkeley.
Speaking In
10:00 AM - 10:55 AM
Thursday, June 11
Since the first FDA approved bispecific antibody Blincyto hit the market in 2015, a wave of new…